2020
Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy.
Eldirany SA, Ho M, Bunick CG. Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy. The Yale Journal Of Biology And Medicine 2020, 93: 19-27. PMID: 32226331, PMCID: PMC7087057.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalBiological ProductsHumansInterleukin-17Interleukin-23Molecular Targeted TherapyNeeds AssessmentPsoriasisReceptors, CytokineTranslational Research, BiomedicalTumor Necrosis Factor-alphaConceptsBiologic therapyTumor necrosis factor alphaFirst-line treatmentTreatment of psoriasisNecrosis factor alphaClinical responseInterleukin-17Interleukin-23Line treatmentPrescribing practicesPsoriasis therapyInflammatory disordersTreatment optionsTherapeutic decisionsClinical dataFactor alphaPatient safetyTherapySignificant differencesBiologic medicinesDrugsEpitope locationMolecular differencesTreatmentMedications
2014
Perspectives on Physiology and Medicine from Nobel Prize Winners: The 64th Lindau Nobel Laureate Meeting
Bunick CG. Perspectives on Physiology and Medicine from Nobel Prize Winners: The 64th Lindau Nobel Laureate Meeting. Journal Of Investigative Dermatology 2014, 134: 2853-2855. PMID: 25381760, DOI: 10.1038/jid.2014.358.Peer-Reviewed Original Research